Literature DB >> 6150002

Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists.

J L Reid, B C Campbell, C A Hamilton.   

Abstract

Interruption of long-term treatment with alpha 2-adrenergic receptor agonists may be associated with reversal of their hemodynamic effects, clinical and biochemical evidence of increased peripheral sympathetic activity, and behavioral responses similar to those seen after narcotic or alcohol withdrawal. Reactions are most commonly observed after short-acting imidazoline drugs such as clonidine and tiamenidine. Reactions are less common after longer acting agents such as guanfacine. A new management approach to withdrawal has been evaluated, which uses a combination of alpha 1-blockade (prazosin) and cardioselective beta-blockade (atenolol) together with a benzodiazepine (chlordiazepoxide). Withdrawal reactions were not observed in eight patients in whom clonidine was withdrawn under cover of these agents. The mechanism of the withdrawal reaction may involve agonist-induced down regulation of alpha 2-adrenergic receptor affinity, number, or both. Experimental studies with the irreversible alpha-antagonist phenoxybenzamine on the turnover of alpha 2-receptors suggest that recovery of receptor number may be much slower in the brain than in the periphery.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6150002     DOI: 10.1161/01.hyp.6.5_pt_2.ii71

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

Review 1.  Antidepressant Withdrawal and Rebound Phenomena.

Authors:  Jonathan Henssler; Andreas Heinz; Lasse Brandt; Tom Bschor
Journal:  Dtsch Arztebl Int       Date:  2019-05-17       Impact factor: 5.594

2.  Hyperadrenergic state following acute withdrawal from clonidine used at supratherapeutic doses.

Authors:  N J Sarlis; O Caticha; J L Anderson; C Kablitz; F S Shihab
Journal:  Clin Auton Res       Date:  1996-04       Impact factor: 4.435

Review 3.  Clinical consequences of abrupt drug withdrawal.

Authors:  C F George; D Robertson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

Review 4.  Sympathomimetic Toxidromes and Other Pharmacological Causes of Acute Hypertension.

Authors:  Andrew King; Mirjana Dimovska; Luke Bisoski
Journal:  Curr Hypertens Rep       Date:  2018-02-24       Impact factor: 5.369

5.  Avoiding Adverse Drug Withdrawal Events When Stopping Unnecessary Medications According to the STOPPFrail Criteria.

Authors:  Joseph T Hanlon; Jennifer Tjia
Journal:  Sr Care Pharm       Date:  2021-03-01

Review 6.  Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders.

Authors:  Tamara Pringsheim; Michael S Okun; Kirsten Müller-Vahl; Davide Martino; Joseph Jankovic; Andrea E Cavanna; Douglas W Woods; Michael Robinson; Elizabeth Jarvie; Veit Roessner; Maryam Oskoui; Yolanda Holler-Managan; John Piacentini
Journal:  Neurology       Date:  2019-05-07       Impact factor: 11.800

7.  Use of Prazosin for Pediatric PTSD-Associated Nightmares and Sleep Disturbances: A Retrospective Chart Review.

Authors:  Brooks R Keeshin; Qian Ding; Angela P Presson; Steven J Berkowitz; Jeffrey R Strawn
Journal:  Neurol Ther       Date:  2017-07-28

Review 8.  α 2-Adrenoceptors: Challenges and Opportunities-Enlightenment from the Kidney.

Authors:  William A Pettinger; Edwin K Jackson
Journal:  Cardiovasc Ther       Date:  2020-04-29       Impact factor: 3.023

Review 9.  European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.

Authors:  Veit Roessner; Heike Eichele; Jeremy S Stern; Liselotte Skov; Renata Rizzo; Nanette Mol Debes; Péter Nagy; Andrea E Cavanna; Cristiano Termine; Christos Ganos; Alexander Münchau; Natalia Szejko; Danielle Cath; Kirsten R Müller-Vahl; Cara Verdellen; Andreas Hartmann; Aribert Rothenberger; Pieter J Hoekstra; Kerstin J Plessen
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-11-10       Impact factor: 4.785

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.